Which specific inflammatory mediators does ketotifen inhibit?

Ketotifen inhibits the release of inflammatory mediators, though specific names are not detailed in the source. Its mechanism is described as combined: stabilization of mast cell membranes with inhibition of degranulation, and $H_1$-histamine receptor blockade. It is also noted that ketotifen suppresses immune cell chemotaxis.

Can ketotifen be used to relieve an acute bronchial asthma attack?

No. The drug has no bronchodilatory activity and is used exclusively for the baseline therapy (prophylaxis) of asthma.

Why is the bioavailability of ketotifen only 50% despite near-complete absorption from the GI tract?

This is due to the first-pass hepatic effect, where half of the absorbed drug is metabolized before entering the systemic circulation.

To which chemical group does ketotifen belong?

It is a tricyclic structure containing sulfur and nitrogen atoms in the central ring, structurally close to antihistamines.

Ketotifen: Mechanism, Pharmacokinetics and Clinical Use

Ketotifen

For medical students2 min readUpdated 2026-10-10

Ketotifen is a dual-action antiallergic agent affecting respiratory tract function. The drug combines the properties of a mast cell stabilizer and an $H_1$-histamine receptor blocker, primarily used for the maintenance (baseline) therapy of allergic diseases.

Pharmacological groupDual-action antiallergic agents

Chemical structureTricyclic compound (containing sulfur and nitrogen)

Dosage formsTablets and capsules, 0.001 g (1 mg)

Site of actionMast cell membranes and $H_1$-histamine receptors

Half-life3–5 hours

Mechanism of Action (Pharmacodynamics)

Ketotifen possesses a unique dual mechanism that distinguishes it from classical antihistamines and pure cromones (such as cromolyn sodium or nedocromil sodium).

Mast cell membrane stabilization: The drug reliably blocks the degranulation process, preventing the release of allergic and inflammatory mediators into tissues.
$H_1$-histamine receptor blockade: Acts as a competitive histamine antagonist. Blocking these receptors prevents the initiation of the intracellular calcium cascade and subsequent smooth muscle contraction.

Additionally, the drug inhibits the release of inflammatory mediators and suppresses the chemotaxis of immune cells to the site of an allergic reaction. Structurally, it is a tricyclic compound (containing sulfur and nitrogen atoms in the central ring), which is very similar to traditional antihistamines.

Pharmacokinetics

After oral administration, the drug is almost completely absorbed from the gastrointestinal tract. However, its ultimate bioavailability is only about 50%. This pharmacokinetic phenomenon is due to a pronounced first-pass hepatic metabolism, where a significant portion of the active substance is metabolized before reaching the systemic circulation. The half-life ($t_{1/2}$) is relatively short, at 3–5 hours.

Indications for Use

The drug is prescribed exclusively for maintenance therapy and the prophylaxis of allergic conditions. The main indications include:

Prophylaxis of bronchial asthma attacks
Atopic dermatitis
Hay fever (allergic rhinoconjunctivitis)
Food allergies

Critical for clinical practice: Ketotifen does not induce bronchodilation. It is entirely unsuitable for relieving acute asthma attacks. Emergency relief requires drugs with a different mechanism of action (e.g., beta-2 adrenergic agonists).

Adverse Effects

Due to its systemic action and ability to cross the blood-brain barrier, the drug causes several characteristic adverse reactions:

Central nervous system: Pronounced sedative effect, drowsiness, slowed psychomotor reactions (patients must be warned about the dangers of driving).
Gastrointestinal and metabolic: Dry mouth, nausea, clinically significant weight gain.
Other reactions: Dizziness, thrombocytopenia (reduced platelet count in peripheral blood).

Dosage Forms and Administration

The drug is available in solid dosage forms: tablets and capsules containing 0.001 g (1 mg). It is administered orally with meals. The standard dosing regimen to maintain therapeutic concentration is twice daily.

Prescription example: Rp.: Tab. Ketotifeni 0.001 D.t.d. N. 30 S. Take 1 tablet orally twice daily with meals.

Mnemonic

KETI: Keeps mast cells stable, Eats a lot (side effect: weight gain), Tires the CNS (sedation), Inhibits allergies ($H_1$-receptor blockade).

Frequently asked questions

Which specific inflammatory mediators does ketotifen inhibit?: Ketotifen inhibits the release of inflammatory mediators, though specific names are not detailed in the source. Its mechanism is described as combined: stabilization of mast cell membranes with inhibition of degranulation, and $H_1$-histamine receptor blockade. It is also noted that ketotifen suppresses immune cell chemotaxis.
Can ketotifen be used to relieve an acute bronchial asthma attack?: No. The drug has no bronchodilatory activity and is used exclusively for the baseline therapy (prophylaxis) of asthma.
Why is the bioavailability of ketotifen only 50% despite near-complete absorption from the GI tract?: This is due to the first-pass hepatic effect, where half of the absorbed drug is metabolized before entering the systemic circulation.
To which chemical group does ketotifen belong?: It is a tricyclic structure containing sulfur and nitrogen atoms in the central ring, structurally close to antihistamines.

Go deeper

Differences between ketotifen and pure membrane stabilizers (cromolyn sodium, nedocromil sodium).
Mechanism of mast cell degranulation and the role of the intracellular calcium cascade.
Classification and pharmacodynamics of 1st and 2nd generation $H_1$-antihistamines.
Leukotriene inflammatory pathway and drug targets (montelukast, zileuton).
Anti-IgE therapy (omalizumab) in the treatment of severe allergic diseases.